Tissue plasminogen activator and gas for diabetic premacular hemorrhage.
OBJECTIVE
To report the effect of intravitreal injection of tissue plasminogen activator and gas for the treatment of diabetic premacular hemorrhage.


METHODS
Five eyes of five consecutive patients with fresh diabetic premacular hemorrhage and previous panretinal photocoagulation were treated with intravitreal injection of 50 microg of tissue plasminogen activator, and 0.3 ml of sulfur hexafluoride. After intravitreal injection, patients maintained a prone position for 3 days and were followed for an average of 7 months (range, 6 to 8 months).


RESULTS
All eyes had clearing of the premacular hemorrhage with improved visual acuity. Three eyes with no visible fibrovascular proliferation required 3 weeks to resorb the hemorrhage, and two eyes with active fibrovascular proliferation needed 2 months to resorb the intravitreal hemorrhage.


CONCLUSIONS
Intravitreal injection of tissue plasminogen activator and gas may be an effective way to treat fresh diabetic premacular hemorrhage.
Yang
C M
CM
Department of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan.
Chen
M S
MS
D000328:Adult; D003930:Diabetic Retinopathy / Q000150:complications / Q000188:drug therapy*; D005342:Fibrinolysis; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D007267:Injections; D008875:Middle Aged; D016684:Prone Position; D012166:Retinal Hemorrhage / Q000150:complications / Q000188:drug therapy*; D015861:Retinal Neovascularization / Q000209:etiology / Q000517:prevention & control; D013459:Sulfur Hexafluoride / Q000627:therapeutic use*; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*; D016896:Treatment Outcome; D014792:Visual Acuity
D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator; D013459:Sulfur Hexafluoride